Curve Therapeutics April 2024 Conference Attendance

Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces activity at the following scientific and investor conferences during April 2024.

Anglonordic Life Science Conference, London, United Kingdom
18 April 2024
Attending: Simon Kerry, Chief Executive Officer
Panel Title: Simon Kerry participating in ‘If I Knew Then What I Know Now’ panel
Panel Time: 16:15pm GMT

BioTrinity, London, United Kingdom
23-24 April 2024
Attending: Simon Kerry, Chief Executive Officer

New Modalities: Innovations in peptides as biotherapeutics, London, United Kingdom
25 April 2024
Attending: Ali Tavassoli, Chief Scientific Officer
Presentation title: Platforms for the intracellular generation and high-throughput screening of cyclic peptide libraries
Presentation time: 15:10pm GMT

If you would like to meet with a member of the team at any of these events, please get in touch.


For more information, please contact:

Curve Therapeutics
Simon Kerry
Chief Executive Officer

Optimum Strategic Communications
Mary Clark, Vici Rabbetts, Joshua Evans
+44 (0) 208 078 4357

About Curve Therapeutics

Curve Therapeutics is a private biotechnology company pioneering a revolutionary intracellular screening platform to enable the discovery of innovative therapeutics that address complex and challenging disease targets with the potential to transform the lives of patients. Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. Curve is backed by blue chip investors including Advent Life Sciences, Epidarex Capital, Pfizer Ventures, Columbus Venture Partners and British Patient Capital. Curve has a US$1.7bn global research collaboration with MSD the trade name of Merck & Co., Inc., Kenilworth, NJ USA, to discover and validate modulators of up to five therapeutic targets using its Microcycle® technology, initially for oncology and neurology indications. For more information visit:

About Curve’s Microcycle® platform

Curve has developed an IP-protected, mammalian cell platform technology for functional screening and enrichment of diverse hexameric cyclic peptide Microcycle® libraries to identify those library members that have the desired biological activity against a therapeutic target. Curve’s platform allows direct screening for biologically active library members inside mammalian cells and facilitates small molecule hit-to-lead programmes. A key advantage of the technology is that both the library and the target are present in all of their native conformations within a cell. Uniquely, the compact size and rigid structure of Microcycles® enables the design of non-peptide small molecule leads. The platform can be used for a wide range of therapeutically relevant targets, including protein-protein and protein-DNA interactions and has been used by Curve to develop a pipeline of cancer programmes against targets including a dual HIF-1/HIF-2 inhibitor and an inhibitor of ATIC homodimerization.